By Jason Derry —

Pharmacopeia and Wyeth have announced that the two
companies have agreed to an exclusive license relating to the
development and commercialization of therapeutics from Pharmacopeia's JAK3
inhibitor technology.  Under the
agreement, Pharmacopeia has the right to therapeutics relating to
dermatological and ocular diseases by topical administration, while Wyeth has
rights to develop products related to all other indications and forms of
administration.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.